The Biology and Role of Interleukin-32 in Tuberculosis

Abstract EN

Tuberculosis, caused by Mycobacterium tuberculosis, remains a leading cause of morbidity and mortality globally, with nearly 10.4 million new cases of incidence and over 1.7 million deaths annually.

Drug-resistant M.

tuberculosis strains, especially multidrug-resistant or extensively drug-resistant strains, have further intensified the problem associated with tuberculosis control.

Host-directed therapy is a promising alternative for tuberculosis control.

IL-32 is increasingly recognized as an important host molecule against tuberculosis.

In this review, we highlight the proinflammatory properties of IL-32 and the mode of action of IL-32 in mycobacterial infections to inspire the development of novel immunity-based countermeasures and host-directed therapies against tuberculosis.